Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02503332 · ClinicalTrials.gov registry record · Phase 2
Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic Atrophy
A Phase 2 study, sponsored by Apellis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 246
- Enrollment target
NCT02503332 is a Phase 2 study that has completed, run by Apellis Pharmaceuticals. The registered enrollment target is 246 participants.
The verdict
NCT02503332, a Phase 2 study, has completed, sponsored by Apellis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 246 participants
- Enrollment target
Study Summary
The primary objectives of the study are to assess the safety, tolerability and evidence of activity of multiple intravitreal (IVT) injections of pegcetacoplan in subjects with Geographic Atrophy associated with Age-Related Macular Degeneration (AMD).
Interventions
- DRUG Pegcetacoplan
- OTHER Sham Procedure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 246 participants |
| Start Date | 2015-09-24 |
| Est. Completion | 2018-01-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02503332
The ClinicalTrials.gov registry entry for NCT02503332 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 246 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Apellis Pharmaceuticals, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pegcetacoplan is the first listed.
NCT02503332 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02503332 about?
NCT02503332 is a clinical study titled "Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic Atrophy". The primary objectives of the study are to assess the safety, tolerability and evidence of activity of multiple intravitreal (IVT) injections of pegcetacoplan in subjects with Geographic Atrophy associated with Age-Related Macular Degeneration (AMD).
What is the current status of trial NCT02503332?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 246 participants. The study started on 2015-09-24. Estimated completion is 2018-01-17.
What interventions are being tested in trial NCT02503332?
The interventions under investigation include: Pegcetacoplan (DRUG), Sham Procedure (OTHER).
Who is sponsoring clinical trial NCT02503332?
This trial is sponsored by Apellis Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.